images

The Fascinating History and Promising Future of Fecal Microbiota Transplantation (FMT)

In the dynamic world of medicine, there is a need for innovative treatments to address challenging clinical conditions.  Fecal Microbiota Transplantation (FMT) stands out as a unique and innovative treatment that has garnered significant attention for its potential to restore gut homeostasis and treat a variety of gastrointestinal and non-gastrointestinal diseases. While it may sound like a modern invention, FMT's origins trace back over 1,700 years 1–7. In this blog, we will explore the rich history of FMT, its current applications, and the exciting future it holds in the treatment of various diseases.

A Journey Through History: From Ancient Practices to Modern Medicine

 

Ancient Beginnings

FMT’s roots can be traced back to 4th century China, nearly 1,700 years ago. Ge Hong, a well-known traditional Chinese medical practitioner, documented the use of "yellow soup," a mixture containing fecal matter, to treat severe diarrhea and food poisoning. This early form of fecal transplantation was a cornerstone of ancient Chinese medicine, highlighting the longstanding recognition of the gut's role in health 6,8. In fact, this is not the only account of the use of fecal material, as the practice continued into the 16th century when Li Shizhen included fecal transplantation in his comprehensive medical text, "Ben Cao Gang Mu," solidifying the therapeutic role of fecal matter in traditional Chinese medicine 2,8.

Modern Rediscovery

The concept of FMT re-emerged within clinical content in the mid-20th century. In 1958, Dr. Ben Eiseman, published a landmark case study on the use of fecal enemas to treat pseudomembranous colitis, a severe colon inflammation often caused by antibiotic use, a condition now known to be primarily caused by Clostridioides difficile 9,10 Then, in 1988, Dr. Thomas Borody performed his first FMT and published a case series suggesting its efficacy in treating non-infectious diseases like Ulcerative Colitis 11. These seminal case series demonstrated the therapeutic potential of FMT to restore intestinal health by reintroducing a healthy microbial community, laying the groundwork for subsequent clinical research 3,8,12.

Current Clinical Applications of FMT

Since the re-application of FMT in clinical practice, its use has gained traction, particularly in the 21st century, as researchers and clinicians began to recognize the importance of the gut microbiome in overall health. Specifically, over the last decade, there has been increased scientific and clinical research into how FMT can modulate the gut microbiome, improve health, and tackle areas of unmet medical need, including gastrointestinal and non-gastrointestinal conditions 1,3–5,7.

Revolutionizing C. difficile Treatment

Today, the most well-established and widely accepted use of FMT is in the treatment of recurrent Clostridioides difficile (C. difficile) infections. C. difficile infections remain a significant healthcare burden, with long-term cure rate using traditional treatments, such as antibiotics, being low and associated with recurrence rates as high as 30%13–16.

FMT has emerged as a highly effective treatment modality for recurrent CDI, with clinical trials demonstrating cure rates exceeding 90% in patients who have failed standard antibiotic therapy 16–18. FMT has demonstrated the ability to decolonize and prevent the recurrence of C. difficile with high success rates and favourable safety profiles, leading to higher rates of overall survival, shorter hospital stays, and lower rates of bloodstream infection 5,17,19–24. Overall, FMT has been shown to be effective and has superior long-term efficacy compared to other medical treatments in C. difficile 6,15,25.

Expanding Clinical Horizons

While CDI remains the primary indication for FMT, the last decade has seen a surge in scientific and clinical research exploring how modifications of the gut microbiome via FMT can address various unmet medical needs. The promising outcomes of FMT in improving symptoms and altering the gut microbiota in CDI patients have spurred research into its efficacy for a broader spectrum of both gastrointestinal (GI) and non-GI disorders 1,3–5,7.  

Gastrointestinal Disorders

There is a growing body of literature indicating that FMT may be a valuable treatment option for various GI disorders, including Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS) 26–31. Studies have suggested that FMT may induce modest remission of around 30-45%, with response rates higher in patients with ulcerative colitis, although results are mixed, necessitating further research 32–36. Similarly, some studies report symptomatic improvement in IBS patients following FMT, with response rates of over 50%, although variability in study designs and patient responses highlights the need for standardized approaches 29,37–39.

Non-Gastrointestinal Disorders

The therapeutic potential of FMT may not be confined to GI diseases. An increasing number of studies have examined its application in treating a variety of non-GI disorders, including metabolic disorders 5,40–44, autism spectrum disorder 45–47, Parkinson’s disease 48–50, Alzheimer's disease 51–54 and multiple sclerosis 55,56. The connection between gut microbiota and systemic health suggests that FMT could become a treatment modality for conditions influenced by the gut-brain axis, metabolic pathways, and immune system function 4,57–69.

Conclusion

The history of FMT is a testament to the enduring importance of the gut in health and disease. From ancient remedies to cutting-edge science, FMT has evolved into a powerful treatment with vast potential. As research continues, FMT may unlock new frontiers in medicine, offering a possible treatment for many areas of unmet need. The journey of FMT is far from over, and its future promises to be as fascinating as its past.

References: 1. Allegretti, J. R. et al. 2019, 2. Borody, T. J. et al. 2014, 3. Brandt, L. J. & Aroniadis, O. C. 2013, 4. Choi, H. H. & Cho, Y.-S. 2016, 5. Rinott, E. et al2021, 6. Ser, H.-L. et al. 2021, 7. Xu, M.-Q. 2015, 8. Zhang, F. et al. 2012, 9. Eiseman, B. et al. 1958, 10. George, R. H. et al. 1978, 11. Borody, T. J. et al. 1989, 12. de Groot, P. F. et al. 2017, 13. Drekonja, D. et al. 2015, 14. Hui, W. et al. 2019, 15. Khan, M. Y. et al. 2018, 16. Quraishi, M. N. et al. 2017, 17. Basson, A. R. et al. 2020, 18. Gough, E. et al. 2011, 19. Austin, M. et al. 2014, 20. Gerardin, Y. et al. 2021, 21. Ianiro, G. et al. 2019, 22. Kelly, C. R. et al. 2016, 23. McCune, V. L. et al. 2014, 24. Youngster, I. et al. 2014, 25. Moayyedi, P. et al. 2017, 26. Aldars-García, L. et al. 2021, 27. Anderson, J. L. et al. 2012, 28. Cruz-Aguliar, R. M. et al. 2019, 29. El‐Salhy, M. et al. 2022, 30. Ianiro, G. et al. 2019, 31. Tan, P., Li, X. et al. 2020, 32. Arora, U. et al. 2024, 33. Boicean, A. et al. 2023, 34. Costello, S. P. et al. 2019, 35. Liu, H., Li, J. et al. 2023, 36. Paramsothy, S. et al. 2017, 37. El‐Salhy, M. et al. 2024, 38. Körner, E. & Lorentz, A. 2023, 39. Su, Q. et al. 2023, 40. Allegretti, J. R. et al. 2021, 41. Kootte, R. S. et al. 2017, 42. Proença, I. M. et al. 2020, 43. Rinott, E. et al. 2021, 44. Zhang et al. 2019, 45. Kang, D.-W. et al. 2017, 46. Kang, D.-W. et al. 2019, 47. Li, N. et al. 2021, 48. Huang, H. et al. 019, 49. Segal, A. et al. 2021, 50. Sun, M.-F. et al. 2018, 51. Chen, X. et al. 2023, 52. Hazan, S. 2020, 53. Nassar, S. T. et al. 2022, 54. Park, S.-H. et al. 2022, 55. Al, K. F. et al. 2022, 56. Engen, P. A. et al. 2020, 57. Chen, X. et al. 2013, 58. Cryan, J. F. et al. 2019, 59. Dinan, T. G. & Cryan, J. F. 2017, 60. Ding, X. et al. 2020, 61. Hooper, L. V. et al. 2012, 62. Jendraszak, M. et al. 2021, 63. Liu, Z. et al. 2021, 64. Rhee, S. H. et al. 2009, 65. Rutsch, A. et al. 2020, 66. Skonieczna-Żydecka, K. et al. 2018, 67. Sommer, F. & Bäckhed, F. 2013, 68. Sudo, N. et al. 2004, 69. Wan, Y. et al. 2021.